• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Spartan Capital Securities, LLC Announces Key February Transactions

    3/7/25 4:56:47 PM ET
    $HCTI
    $LIPO
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCTI alert in real time by email

    New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025, reinforcing its position as a trusted financial partner for companies across diverse industries.

    Spartan Capital successfully served as the sole placement agent for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) in a $3.788 million private placement. This financing represents an important milestone in Lipella's efforts to advance its clinical pipeline and address significant unmet medical needs under the leadership of CEO Dr. Jonathan Kaufman.

    The firm also played a key role as Co-Placement Agent in Healthcare Triangle, Inc.'s (NASDAQ:HCTI) $15.2 million private placement, securing $14.2 million of the total offering. The proceeds will support Healthcare Triangle's strategic acquisitions, general corporate purposes, and working capital needs, enabling the company to further its mission of driving digital transformation in healthcare and life sciences through cloud enablement, cybersecurity, and data analytics.

    "These transactions highlight Spartan Capital's ability to deliver meaningful results for our clients," said John Lowry, CEO of Spartan Capital Securities, LLC. "We take pride in our role as a trusted partner, helping companies secure the capital they need to fuel innovation, execute strategic growth initiatives, and drive long-term success. Our investment banking team remains committed to delivering exceptional service and tailored financial solutions across diverse industries."

    Spartan Capital extends its gratitude to Sichenzia Ross Ference Carmel LLP for their expert legal representation of Spartan Capital in the Lipella Pharmaceuticals transaction and Sullivan & Worcester LLP for representing Lipella Pharmaceuticals. Additionally, we appreciate the contributions of RBW Capital Partners LLC (a division of Dawson James Securities, Inc.), Sichenzia Ross Ference Carmel LLP, and Manatt, Phelps & Phillips, LLP in the Healthcare Triangle placement.

    These February transactions exemplify Spartan Capital Securities' ongoing commitment to providing impactful investment banking solutions. With a deep understanding of market dynamics and a focus on delivering strategic financial solutions, Spartan Capital remains dedicated to supporting clients in achieving their long-term goals.

    As we continue into 2025, Spartan Capital is excited about the opportunities ahead and remains committed to delivering excellence in investment banking.

    About Spartan Capital Securities, LLC

    Spartan Capital Securities, LLC is a full-service, integrated financial services firm providing strategic investment banking solutions to high-net-worth individuals and institutions. With deep market expertise and a steadfast commitment to client success, Spartan Capital continues to set the standard for excellence in the financial industry.

    Contact:

    Spartan Capital Securities, LLC

    45 Broadway, 19th Floor

    New York, NY 10006

    [email protected]



    Primary Logo

    Get the next $HCTI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HCTI
    $LIPO

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $HCTI
    $LIPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

      PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange. In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitmen

      6/25/25 3:15:00 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

      PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Spec

      6/20/25 3:19:25 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

      PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled "Systems and Methods of Detecting Interstitial Cystitis." The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions. The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enha

      6/17/25 8:30:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCTI
    $LIPO
    SEC Filings

    See more
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/25/25 3:14:40 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Healthcare Triangle Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Healthcare Triangle, Inc. (0001839285) (Filer)

      6/23/25 5:13:58 PM ET
      $HCTI
      EDP Services
      Technology
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/20/25 4:02:53 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCTI
    $LIPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      4/7/25 7:16:11 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Business Head Kannappan Lakshmanan acquired 304,180 shares, increasing direct ownership by 1,521% to 324,180 units (SEC Form 4)

      4 - Healthcare Triangle, Inc. (0001839285) (Issuer)

      4/2/25 5:13:23 PM ET
      $HCTI
      EDP Services
      Technology
    • Head of M&A Kizhakevilayil Shibu acquired 34,129 shares, increasing direct ownership by 171% to 54,129 units (SEC Form 4)

      4 - Healthcare Triangle, Inc. (0001839285) (Issuer)

      4/2/25 5:12:34 PM ET
      $HCTI
      EDP Services
      Technology

    $HCTI
    $LIPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      5/15/24 4:39:19 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/19/24 6:21:08 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCTI
    $LIPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:09:22 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:00:15 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

      SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      10/17/24 5:00:44 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCTI
    $LIPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Healthcare Triangle, Inc. Appoints Anand Kumar as Interim CEO

      PLEASANTON, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc. (NASDAQ:HCTI) ("Healthcare Triangle," "HCTI" or the "Company"), a frontrunner in healthcare technology has announced the appointment of Anand Kumar as the interim Chief Executive Officer alongside his current role as the Chief Revenue Officer. Anand is committed to leading the Company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, Artificial Intelligence (AI) and Large Language Models (LLM). With a wealth of experience and a track record of successfully leading initiatives, Anand is strategically positioned to guide HCTI through its next phase of

      3/12/24 9:41:00 AM ET
      $HCTI
      EDP Services
      Technology

    $HCTI
    $LIPO
    Financials

    Live finance-specific insights

    See more
    • Healthcare Triangle, Inc. Releases Shareholder Update

      Highlights Market Opportunity and Recent Accretive Acquisition Awarded Top 100 Premier Partner Status at Amazon World Services & Premier Partner Status at Google Cloud PLEASANTON, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (NASDAQ:HCTI) ("HCTI" or the "Company") a leading provider of cloud and data transformation platform and solutions for healthcare and life sciences, today released a shareholder update: Dear Shareholders: Thank you for your continued commitment and investment in Healthcare Triangle, Inc . Our progress over the past year would not have been possible without your trust and belief in our mission. This is our first shareholder update since our

      1/20/22 8:30:00 AM ET
      $HCTI
      EDP Services
      Technology
    • Healthcare Triangle (HCTI) Acquires DevCool, an Electronic Health Record (EHR) Focused Healthcare IT and Managed Services Company

      PLEASANTON, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (HCTI), a leading provider of Healthcare and Life Sciences cloud transformation, managed services and data analytics platform company, announced today that it has acquired DevCool, Inc. ("DevCool"), ranked by Inc. 5000 as among the fastest growing private companies in USA in 2021. DevCool provides EHR Implementation and Managed Services to 6 of the top 10 hospitals in the USA and specializes in providing services to cancer research hospitals and university medical centres. The combined entity will focus on accelerating healthcare providers to adopt cloud technologies in improving clinical, operational, and fin

      12/13/21 8:00:00 AM ET
      $HCTI
      EDP Services
      Technology